U.S. Application Serial No. 09/333,159

Attorney Docket No. MBI099-030RCEM

# Marked Up Copy of Claims, as Amended in the Amendment Filed in Response to the Office Action Dated February 14, 2003

- 1. (Amended Four Times) An isolated nucleic acid molecule, or its complement, wherein the isolated nucleic acid i) encodes a polypeptide which exhibits lipase activity and ii) is selected from the group consisting of:
- a) a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO: 45 or 46;
  - b) a nucleic acid molecule comprising a fragment of SEQ ID NO: 45 or 46;
- c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence encoded by SEQ ID NO: 46;
- d) a nucleic acid molecule which encodes a fragment of the amino acid sequence encoded by SEQ ID NO: 46; and
- e) a nucleic acid molecule which encodes a variant of the amino acid sequence encoded by SEQ ID NO: 46, wherein the nucleic acid molecule hybridizes over its full length in 6× sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50°C with a portion of a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 45 or 46.
- 39. (Twice Amended) The isolated nucleic acid molecule of claim 1, or its complement, wherein the molecule hybridizes <u>over its full length</u> in 6× SSC at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50°C with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 45 or 46.

U.S. Application Serial No. 09/333,159

Attorney Docket No. MBI099-030RCEM

- 33. (Twice Amended) The isolated nucleic acid molecule of claim 30, or its complement, wherein the <u>nucleic acid molecule encodes a polypeptide comprising a fragment</u> which comprises consecutive amino acid residues comprise an immunogenic portion of the protein having the amino acid sequence encoded by SEQ ID NO: 46.
- 32. (Thrice Amended) The isolated nucleic acid molecule of claim 1, or its complement, wherein the nucleic acid molecule encodes a variant of the amino acid sequence encoded by SEQ ID NO: 46, wherein the nucleic acid molecule hybridizes over its full length in 6× SSC at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50°C with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 45 or 46.
- 37. (Thrice Amended) The method of claim 12, wherein the polypeptide is a variant of the polypeptide encoded by SEQ ID NO: 46, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes over its full length in 6× SSC at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50°C with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 45 or 46, or a complement thereof.
- 43. (Amended) An isolated nucleic acid molecule, or its complement, wherein the isolated nucleic acid i) encodes an immunogenic portion of the protein having the amino acid sequence encode by SEQ ID NO: 46 and ii) is selected from the group consisting of:
- a) a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO: 45 or 46;
  - b) a nucleic acid molecule comprising a fragment of SEQ ID NO: 45 or 46;
- c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence encoded by SEQ ID NO: 46;

U.S. Application Serial No. 09/333,159

Attorney Docket No. MBI099-030RCEM

- d) a nucleic acid molecule which encodes a fragment of the amino acid sequence encoded by SEQ ID NO: 46; and
- e) a nucleic acid molecule which encodes a variant of the amino acid sequence encoded by SEQ ID NO: 46, wherein the nucleic acid molecule hybridizes over its full length in 6× sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50°C with a portion of a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 45 or 46.
- 44. (Amended) The isolated nucleic acid molecule of claim 43, or its complement, wherein the molecule hybridizes <u>over its full length</u> in 6× SSC at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50°C with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 45 or 46.
- 54. (Amended) The isolated nucleic acid molecule of claim 43, or its complement, wherein the nucleic acid molecule encodes a variant of the amino acid sequence encoded by SEQ ID NO: 46, wherein the nucleic acid molecule hybridizes over its full length in 6× SSC at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50°C with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 45 or 46.
- 65. (Twice Amended) The method of claim 62, wherein the <u>immunogenic</u> portion is from a polypeptide is a variant of the polypeptide encoded by SEQ ID NO: 46, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes <u>over its full</u> length in 6× SSC at about 45°C, followed by one or more washes in 0.2× SSC, 0.1% SDS at 50°C with a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO: 45 or 46, or a complement thereof.

NiceSite View of PROSITE: PS00120

ExPASy Home page	Site Map	Search ExPASy	Contact us	PROSITE
Hosted by NCSC US	Mirror sites:	Canada China Korea S	witzerland Taiwan	
Search PROSITE		for		

## **NiceSite View of PROSITE: PS00120**

Entry name	LIPASE_SER							
Accession number	PS00120							
Entry type	PATTERN							
Date	APR-1990 (CREATED); NOV-1997 (DATA UPDATE); JUL-1998 (INFO UPDATE).							
PROSITE documentation	PDOC00110							
Name and cha	aracterization of the entry							
Description	Lipases, serine active site.							
Pattern	[LIV]-x-[LIVFY]-[LIVMST]-G-[HYWV]-S-x-G-[GSTAC].							
Numerical res	sults							
Number differen     Number differen     Number     Number     Number pattern o     Precisio     Recall (      Comments     Taxonor     Maximu	mber of hits in SWISS-PROT: 113 hits in 113 different sequences of hits on proteins that are known to belong to the set under consideration: 73 hits in 73 at sequences of hits on proteins that could potentially belong to the set under consideration: 2 hits in 2 at sequences of false hits (on unrelated proteins): 38 hits in 38 different sequences of known missed hits: 10 of partial sequences which belong to the set under consideration, but which are not hit by the or profile because they are partial (fragment) sequences: 2 in (true hits / (true hits + false positives)): 65.77 % true hits / (true hits + false negatives)): 87.95 %  mic range: Eukaryotes, Prokaryotes (Bacteria) im known number of repetitions of the pattern in a single protein: 1 ting' site in the pattern: 7,active_site							
	True positive hits:  LCAT_CLEGL (035502), LCAT_HUMAN (P04180), LCAT_MOUSE (P16301), LCAT_PAPAN (Q08758), LCAT_RABIT (P53761), LCAT_RAT (P18424), LCAT_TATKG (035840), LICH_HUMAN (P38571), LIP1_CANFA (P06857), LIP1_HUMAN (P54315), LIP1_RAT (P54316), LIP2_HUMAN (P54317), LIP2_RAT (P54318), LIP3_DROME (046108), LIP_BURCE (P22088), LIP_PSEAE (P26876), LIP_PSEPR (P08658), LIP_PSEGL (Q05489), LIP_PSESS (P25275), LIP_PSESP (P26877), LIP_RHIMI (P19515),							

```
LIPA_PSEFL (<u>P26504</u>), LIPB_PSEFL (<u>P41773</u>), LIPB_AERHY (P40600),
                 LIPG_BOVIN (<u>Q29458</u>), LIPG_CANFA (<u>P80035</u>), LIPG_HUMAN (<u>P07098</u>),
                 LIPG_RAT
                              (P04634), LIPH_HUMAN (P11150), LIPH_MOUSE (P27656),
                 LIPH_RAT
                              (P07867), LIPL_BOVIN (P11151), LIPL_CAVPO (P11153),
                 LIPL_CHICK (P11602), LIPL_FELCA (P55031), LIPL_HUMAN (P06858),
                 LIPL_MOUSE (<u>P11152</u>), LIPL_MUSVI (<u>046647</u>), LIPL_PAPAN (<u>P49060</u>),
                              (P49923), LIPL_RAT (Q06000), LIPL_SHEEP (Q29524),
                 LIPL_PIG
                 LIPP_CAVPO (P50903), LIPP_HORSE (P29183), LIPP_HUMAN (P16233),
                 LIPP_MYOCO (<u>Q64425</u>), LIPP_PIG (<u>P00591</u>), LIPP_RABIT (<u>Q02157</u>),
                              (P27657), MDLA_PENCA (P25234), PA11_DOLMA (Q06478),
                 LIPP_RAT
                 PA12_DOLMA (<u>P53357</u>), PA1_POLAN (<u>Q9U6W0</u>), PA1_VESMC
                                                                                 (P51528),
                 PA1_VESVU (<u>P49369</u>), PAF2_BOVIN (<u>P79106</u>), PAF2_HUMAN (<u>Q99487</u>),
PAFA_BOVIN (<u>Q28017</u>), PAFA_CANFA (<u>Q28262</u>), PAFA_CAVPO (<u>P70683</u>),
                 PAFA_CHICK (Q90678), PAFA_HUMAN (Q13093), PAFA_MOUSE (Q60963),
                 PHAB_PSEOL (<u>P26495</u>), YB54_YEAST (<u>P38139</u>), YJ77_YEAST (<u>P47145</u>),
                 YR15_MYCTU (007214)
                 False negative hits (sequences which belong to the set under consideration, but which
                 have not been picked up by the pattern or profile):
                LCAT_CHICK (P53760), LCAT_ELTOU (035573), LCAT_MICMN (035724),
                LIP1_DROME (046107), LIP1_MORSP (P19833), LIP1_PSYIM (Q02104),
                 LIP2_MOUSE (<u>P17892</u>), LIP2_MYOCO (<u>Q64424</u>), LIP3_MORSP (<u>P24640</u>),
                 PAFA_CAEEL (Q22943)
                 'Potential' hits (partial sequences which belong to the set under consideration, but
                 which are not hit by the pattern or profile because they are partial (fragment)
                 sequences):
SWISS-PROT
                 LCAT_PIG
                              (P30930), LIPT_BURCE (P29605)
                 Sequences which could potentially belong to the set under consideration:
                 FAEA_ASPNG (042807), FAEA_ASPTU (042815)
                 False positive hits (sequences which do not belong to the set under consideration):
                 CUTI_BOTCI (<u>Q00298</u>), ESL2_MYCGE (<u>Q49418</u>), ESL2_MYCPN (<u>P75311</u>),
                 ESL3_MYCGE (Q49421), ESL3_MYCPN (P75268), EST6_DROMA (P47982),
                 EST6_DROME (P08171), EST6_DROSI (Q08662), ESTA_DROPS (P25727),
                 ESTB_DROPS (P25726), ESTC_DROPS (P25725), ESTP_DROME (P18167),
                GLR3_HUMAN (<u>P42263</u>), GLR3_RAT (<u>P19492</u>), HMDH_HALVO (<u>Q59468</u>),
MAO2_RICPR (<u>Q9ZDF6</u>), MX67_SCHPO (<u>Q9Y8G3</u>), PI7A_ORYSA (<u>Q40708</u>),
                 PI7B_ORYSA (<u>Q43360</u>), PIP_BACCO (<u>P46541</u>), RPOB_COXBU (<u>087903</u>),
                TFE3_HUMAN (<u>P19532</u>), TFE3_MOUSE (Q64092), TR16_HUMAN (<u>P08138</u>),
                TR16_RAT
                              (P07174), Y193_HARIN (Q57427), Y4KF_RHISN (P55526),
                YFC5_YEAST (P43571), YGO4_YEAST (P53118), YHN5_YEAST (P38796),
                 YJG8_YEAST (P40363), YK79_MYCTU (Q10687), YKD7_CAEEL (Q03565),
                 YL4K_CAEEL (Q20076), YM23_MYCTU (Q10508), YM24_MYCTU (Q10509),
                 YN84_YEAST (P40345), YTXM_BACSU (P23974)
                 Retrieve an alignment of SWISS-PROT true positive hits:
                 [Clustal format, color, condensed view] [Clustal format, color] [Clustal format, plain text]
                 [Fasta format]
PDB
                 1RP1; 1BU8; 1OIL; 2LIP; 3LIP; 1TAH; 1TGL; 3TGL; 4TGL; 5TGL; 1LGY; 1TIB; 1TIC;
Detailed viewl
                 1HPL; 1LPA; 1LPB; 1ETH; 1TIA;
```

<b>ExPASy Home page</b>	Site Map	Sear	ch Ex	PASy	Contact us	PROSITE
Hosted by NCSC U	S Mirror sites:	Canada	China	Korea	Switzerland Taiwan	
Search PROSITE		for				

## PROSITE: PS00120

```
ID
      LIPASE_SER; PATTERN.
AC
      PS00120:
DT
      APR-1990 (CREATED); NOV-1997 (DATA UPDATE); JUL-1998 (INFO UPDATE).
      Lipases, serine active site.
DE
       [LIV] -x-[LIVFY] - [LIVMST] -G-[HYWV] -S-x-G-[GSTAC].
PA
NR
      /RELEASE=40.7,103373;
      /TOTAL=113(113); /POSITIVE=73(73); /UNKNOWN=2(2); /FALSE_POS=38(38);
NR
NR
      /FALSE_NEG=10; /PARTIAL=2;
CC
      /TAXO-RANGE=??EP?; /MAX-REPEAT=1:
CC
      /SITE=7,active_site;
DЯ
      035502, LCAT_CLEGL, T; P04180, LCAT_HUMAN, T; P16301, LCAT_MOUSE, T;
DR
      Q08758, LCAT_PAPAN, T; P53761, LCAT_RABIT, T; P18424, LCAT_RAT , T;
      035840, LCAT_TATKG, T; P38571, LICH_HUMAN, T; P06857, LIP1_CANFA, T;
DR
      P54315, LIP1_HUMAN, T; P54316, LIP1_RAT , T; P54317, LIP2_HUMAN, T;
DR
DR
      P54318, LIP2_RAT , T; 046108, LIP3_DROME, T; P22088, LIP BURCE , T;
DR
      P26876, LIP_PSEAE , T; P08658, LIP_PSEFR , T; Q05489, LIP_PSEGL , T;
DR
      \underline{P25275}, LIP_PSES5 , T; \underline{P26877}, LIP_PSESP , T; \underline{P19515}, LIP_RHIMI ,
DR
      P21811, LIP_RHIOR , T; P10335, LIP_STAAU , T; Q02510, LIP_STAEP , T;
DR
      P04635, LIP_STAHY , T; 059952, LIP_THELA , T; P15493, LIP_VIBCH , T;
DR
      P26504, LIPA_PSEFL, T; P41773, LIPB_PSEFL, T; P40600, LIPE_AERHY, T;
DR
      Q29458, LIPG_BOVIN, T; P80035, LIPG_CANFA, T; P07098, LIPG_HUMAN, T;
DR
      P04634, LIPG_RAT , T; P11150, LIPH_HUMAN, T; P27656, LIPH_MOUSE, T;
DR
      P07867, LIPH_RAT , T; P11151, LIPL_BOVIN, T; P11153, LIPL_CAVPO, T;
DR
      P11602, LIPL_CHICK, T; P55031, LIPL_FELCA, T; P06858, LIPL_HUMAN, T;
DR
      P11152, LIPL_MOUSE, T; O46647, LIPL_MUSVI, T; P49060, LIPL_PAPAN, T;
DR
      P49923, LIPL_PIG , T; Q06000, LIPL_RAT , T; Q29524, LIPL_SHEBP, T;
      P50903, LIPP_CAVPO, T; P29183, LIPP_HORSE, T; P16233, LIPP_HUMAN, T;
DR
      Q64425, LIPP_MYOCO, T; P00591, LIPP_PIG , T; Q02157, LIPP_RABIT, T;
DR
      P27657, LIPP_RAT , T; P25234, MDLA_PENCA, T; Q06478, PA11_DOLMA, T; P53357, PA12_DOLMA, T; Q9U6W0, PA1_POLAN , T; P51528, PA1_VESMC , T;
DR
DR
      P49369, PA1_VESVU , T; P79106, PAF2_BOVIN, T; Q99487, PAF2_HUMAN, T; Q28017, PAFA_BOVIN, T; Q28262, PAFA_CANFA, T; P70683, PAFA_CAVPO, T;
DR
DR
DR
      \underline{\text{Q90678}}, PAFA_CHICK, T; \underline{\text{Q13093}}, PAFA_HUMAN, T; \underline{\text{Q60963}}, PAFA_MOUSE, T;
      P26495, PHAB_PSEOL, T; P38139, YB54_YEAST, T; P47145, YJ77_YEAST, T;
DR
DR
      007214, YR15_MYCTU, T;
DR
      <u>P30930</u>, LCAT_PIG , P; <u>P29605</u>, LIPT_BURCE, P;
      P53760, LCAT_CHICK, N; O35573, LCAT_ELIQU, N; O35724, LCAT_MICMN, N;
DR
      046107, LIP1_DROME, N; P19833, LIP1_MORSP, N; Q02104, LIP1_PSYIM, N;
DR
      P17892, LIP2_MOUSE, N; Q64424, LIP2_MYOCO, N; P24640, LIP3_MORSP, N;
DR
DR
      Q22943, PAFA_CAEEL, N;
DR
      042807, FAEA_ASPNG, ?; 042815, FAEA_ASPTU, ?;
DR
      Q00298, CUTI_BOTCI, F; Q49418, ESL2_MYCGE, F; P75311, ESL2_MYCPN, F;
      Q49421, ESL3_MYCGE, F; P75268, ESL3_MYCPN, F; P47982, EST6_DROMA, F; P08171, EST6_DROME, F; Q08662, EST6_DROSI, F; P25727, ESTA_DROPS, F;
DR
DR
      P25726, ESTB_DROPS, F; P25725, ESTC_DROPS, F; P18167, ESTP_DROME, F; P42263, GLR3_HUMAN, F; P19492, GLR3_RAT , F; Q59468, HMDH_HALVO, F;
DR
DR
      Q9ZDF6, MAO2_RICPR, F; Q9Y8G3, MX67_SCHPO, F; Q40708, P17A_ORYSA, F;
DR
      Q43360, PI7B_ORYSA, F; P46541, PIP_BACCO , F; O87903, RPOB_COXBU, F; P19532, TFE3_HUMAN, F; Q64092, TFE3_MOUSE, F; P08138, TR16_HUMAN, F;
DR
DR
      P07174, TR16_RAT , F; Q57427, Y193_HAEIN, F; P55526, Y4KF_RHISN, F; P43571, YFC5_YEAST, F; P53118, YGO4_YEAST, F; P38796, YHN5_YEAST, F;
DR
DR
DR
      P40363, YJG8_YEAST, F; Q10687, YK79_MYCTU, F; Q03565, YKD7_CAEEL, F;
```

95/15/2003	14:22	FAX	617	374	0074
PROSITE:	PS001	20			

LEGAL DEPT.

**2**029

Page 2 of 2

DR	Q20076, YL4K_CAEEL, F; Q10508, YM23_MYCTU, F; Q10509,	YM24_MYCTU,	F;
DR	P40345, YN84_YEAST, F; P23974, YTXM_BACSU, F;		
3D	1RP1; 1BU8; 1OIL; 2LIP; 3LIP; 1TAH; 1TGL; 3TGL; 4TGL;	5TGL; 1LGY;	1TIB;
3D	1TIC; 1HPL; 1LPA; 1LPB; 1ETH; 1TIA;		
DO	PDOC00110;		

### NiceSite - a user-friendly view of this PROSITE entry

If you would like to retrieve all the SWISS-PROT entries referenced in the DR lines of this entry (with the exception of false positive hits), you can enter a file name. These entries will then be saved to a file under this name in the directory outgoing of the <u>Expasy anonymous ftp server</u>, from where you can download it. (Please note that this temporary file will only be kept for 1 week.)

File name:	 	·		·	 



ExPASy Home page	Site Map	Search E	xPASy	Contact us	PROSITE
Hosted by NCSC I	JS Mirror sites:	Canada Chin	a Korea S	Switzerland Taiwan	

#### **BioRS HTTP API**

```
LIPASE_SER; PATTERN.
AC
      PS00120;
      APR-1990 (CREATED); NOV-1997 (DATA UPDATE); JUL-1998 (INFO UPDATE).
DT
      Lipases, serine active site.
DE
      [LIV] -x - [LIVFY] - [LIVMST] -G - [HYWV] -S -x -G - [GSTAC].
PA
      /RELEASE=40.7,103373;
NR
      /TOTAL=113(113); /POSITIVE=73(73); /UNKNOWN=2(2); /FALSE_POS=38(38);
NR
NR
      /FALSE_NEG=10; /PARTIAL=2;
      /TAXO-RANGE=??EP?; /MAX-REPEAT=1;
CC
      /SITE=7,active_site;
CC
      O35502, LCAT_CLEGL, T; P04180, LCAT_HUMAN, T; P16301, LCAT_MOUSE, T;
DR
      Q08758, LCAT_PAPAN, T; P53761, LCAT_RABIT, T; P18424, LCAT_RAT
DR
      O35840, LCAT_TATKG, T; P38571, LICH_HUMAN, T; P06857, LIP1_CANFA, T;
DR
      P54315, LIP1_HUMAN, T; P54316, LIP1_RAT , T; P54317, LIP2_HUMAN, T;
DR
      P54318, LIP2_RAT , T; O46108, LIP3_DROME, T; P22088, LIP_BURCE , T; P26876, LIP_PSEAE , T; P08658, LIP_PSEFR , T; Q05489, LIP_PSEGL , T;
DR
DR
      P25275, LIP_PSES5 , T; P26877, LIP_PSESP , T; P19515, LIP_RHIMI , T;
DR
      P21811, LIP_RHIOR , T; P10335, LIP_STAAU , T; Q02510, LIP_STAEP , T;
DR
      P04635, LIP_STAHY , T; O59952, LIP_THELA , T; P15493, LIP_VIBCH , T;
DR
      P26504, LIPA_PSEFL, T; P41773, LIPB_PSEFL, T; P40600, LIPB_AERHY, T;
DR
      Q29458, LIPG_BOVIN, T; P80035, LIPG_CANFA, T; P07098, LIPG_HUMAN, T;
DR
      PO4634, LIPG_RAT , T; P11150, LIPH_HUMAN, T; P27656, LIPH_MOUSE, T;
DŘ
      PO7867, LIPH_RAT , T; P11151, LIPL_BOVIN, T; P11153, LIPL_CAVPO, T;
DR
      P11602, LIPL_CHICK, T; P55031, LIPL_FELCA, T; P06858, LIPL_HUMAN, T;
DR
      P11152, LIPL_MOUSE, T; O46647, LIPL_MUSVI, T; P49060, LIPL_PAPAN, T;
DR
      P49923, LIPL_PIG , T; Q06000, LIPL_RAT , T; Q29524, LIPL_SHEEP, T;
DR
      P50903, LIPP_CAVPO, T; P29183, LIPP_HORSE, T; P16233, LIPP_HUMAN, T;
DR
      Q64425, LIPP_MYOCO, T; P00591, LIPP_PIG , T; Q02157, LIPP_RABIT, T;
DR
      P27657, LIPP_RAT , T; P25234, MDLA_PENCA, T; Q06478, PA11_DOLMA, T;
DR
      P53357, PA12_DOLMA, T; Q9U6W0, PA1_POLAN , T; P51528, PA1_VESMC , T;
DR
      P49369, PA1_VESVU , T; P79106, PAF2_BOVIN, T; Q99487, PAF2_HUMAN, T;
DR
      Q28017, PAFA_BOVIN, T; Q28262, PAFA_CANFA, T; P70683, PAFA_CAVPO, T;
DR
      O90678, PAFA_CHICK, T; Q13093, PAFA_HUMAN, T; Q60963, PAFA_MOUSE, T;
DR
      P26495, PHAB_PSEOL, T; P38139, YB54_YEAST, T; P47145, YJ77_YEAST, T;
DR
      007214, YR15_MYCTU, T;
DR
      P30930, LCAT_PIG , P; P29605, LIPT_BURCE, P;
DR
      P53760, LCAT_CHICK, N; O35573, LCAT_ELIQU, N; O35724, LCAT_MICMN, N; O46107, LIP1_DROME, N; P19833, LIP1_MORSP, N; Q02104, LIP1_PSYIM, N; P17892, LIP2_MOUSE, N; Q64424, LIP2_MYOCO, N; P24640, LIP3_MORSP, N;
DR
DR
DR
DR
      Q22943, PAFA_CAEEL, N;
      O42807, FAEA_ASPNG, ?; O42815, FAEA_ASPTU, ?;
DR
      Q00298, CUTI_BOTCI, F; Q49418, ESL2_MYCGE, F; P75311, ESL2_MYCPN, F;
DR
      Q49421, ESL3_MYCGE, F; P75268, ESL3_MYCPN, F; P47982, EST6_DROMA, F; P08171, EST6_DROME, F; Q08662, EST6_DROSI, F; P25727, ESTA_DROPS, F; P25726, ESTB_DROPS, F; P25725, ESTC_DROPS, F; P18167, ESTP_DROME, F; P42263, GLR3_HUMAN, F; P19492, GLR3_RAT, F; Q59468, HMDH_HALVO, F; Q9ZDF6, MAO2_RICPR, F; Q9Y8G3, MX67_SCHPO, F; Q40708, P17A_ORYSA, F; Q42360, P17A_ORYSA, F;
DR
DR
DR
DR
DR
      Q43360, PI7B_ORYSA, F; P46541, PIP_BACCO , F; O87903, RPOB_COXBU, F;
DR
      P19532, TFE3_HUMAN, F; Q64092, TFE3_MOUSE, F; P08138, TR16_HUMAN, F;
DR
      P07174, TR16_RAT , F; Q57427, Y193_HAEIN, F; P55526, Y4KF_RHISN, F; P43571, YFC5_YEAST, F; P53118, YGO4_YEAST, F; P38796, YHN5_YEAST, F;
DR
DR
      P40363, YJG8_YEAST, F; Q10687, YK79_MYCTU, F; Q03565, YKD7_CAEEL, F;
DR
      Q20076, YL4K_CAEEL, F; Q10508, YM23_MYCTU, F; Q10509, YM24_MYCTU, F; P40345, YN84_YEAST, F; P23974, YTXM_BACSU, F;
DR
DR
      1RP1; 1BU8; 10IL; 2LIP; 3LIP; 1TAH; 1TGL; 3TGL; 4TGL; 5TGL; 1LGY; 1TIB;
3D
      1TIC; 1HPL; 1LPA; 1LPB; 1ETH; 1TIA;
3D
      PDOC00110;
DO
{PDOC00110}
{PS00120; LIPASE_SER}
{BEGIN}
```

\*\*\*\*\*\*\*\*\*

Triglyceride lipases (EC 3.1.1.3) [1] are lipolytic enzymes that hydrolyzes the ester bond of triglycerides. Lipases are widely distributed in animals, plants and prokaryotes. In higher vertebrates there are at least three tissue-specific isozymes: pancreatic, hepatic, and gastric/lingual. These three types of lipases are closely related to each other as well as to lipoprotein lipase (EC 3.1.1.34) [2], which hydrolyzes triglycerides of chylomicrons and very low density lipoproteins (VLDL).

The most conserved region in all these proteins is centered around a serine residue which has been shown [3] to participate, with an histidine and an aspartic acid residue, to a charge relay system. Such a region is also present in lipases of prokaryotic origin and in lecithin-cholesterol acyltransferase (EC 2.3.1.43) (LCAT) [4], which catalyzes fatty acid transfer between phosphatidylcholine and cholesterol. We have built a pattern from that region.

- -Consensus pattern: [LIV]-x-[LIVFY]-[LIVMST]-G-[HYWV]-S-x-G-[GSTAC]
  [S is the active site residue]
- -Sequences known to belong to this class detected by the pattern: ALL.
- -Other sequence(s) detected in Swiss-Prot: 38.
- -Note: Drosophila vitellogenins are also related to lipases [5], but they have lost their active site serine.
- -Last update: November 1997 / Pattern and text revised.
- [ 1] Chapus C., Rovery M., Sarda L., Verger R. Biochimie 70:1223-1234(1988).
- [ 2] Persson B., Bengtsson-Olivecrona G., Enerback S., Olivecrona T., Joernvall H. Eur. J. Biochem. 179:39-45(1989).
- [ 3] Blow D.
  - Nature 343:694-695(1990).
- [4] McLean J., Fielding C., Drayna D., Dieplinger H., Baer B., Kohr W., Henzel W., Lawn R. Proc. Natl. Acad. Sci. U.S.A. 83:2335-2339(1986).
- [ 5] Baker M.E. Biochem. J. 255:1057-1060(1988).

This PROSITE entry is copyright by the Swiss Institute of Bioinformatics (SIB). There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or email to license@isb-sib.ch).

{END}

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**PATENT** Practitioner's Docket No. MBIO99-030RCEM FAX RECEIVED Certificate of Transmission under 37 CFR 1.8 MAY 16 2 nnz I hereby certify that this correspondence is being facsimile transmitted to the GROUP 1500 United States Patent and Trademark Office United States Patent and Trademark Office on 15 May 2003. Mary MacKinnon Typed or printed name of person signing Certificate Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper. Submitted herewith: (2 pages - in duplicate) Transmittal Letter Amendment and (8 pages) Response to Office Action dated February 14, 2003 (9 pages) Clean Copy of Claims, as Amended (2 pages) Marked Up Copy of Claims, as Amended PROSITE website printouts, including from the ExPASY (Expert Protein Analysis System) proteomics server of the (6 pages) Swiss Institute of Bioinformatics (SIB) (http://us.expasy.org/prosite/) (27 pages-including fax cover sheet) Total

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.